Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 14/20 | 0.65 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | KLRK1 | P26718 | 2/20 | 0.41 |
| ▸ | MICA | Q29983 | 2/20 | 0.41 |
| ▸ | RAET1L | Q5VY80 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6869360 | 1.00 | TACR1 (0.65) | TACR1GPBAR1KCNH2KLRK1MICA | |
| SCHEMBL6862680 | 1.00 | TACR1 (0.65) | TACR1GPBAR1KCNH2KLRK1MICA | |
| SCHEMBL5740419 | 0.83 | TACR1 (0.53) | TACR1GPBAR1KCNH2 | |
| SCHEMBL27544426 | 0.78 | TACR1 (0.48) | TACR1KCNH2 | |
| SCHEMBL5741170 | 0.77 | TACR1 (0.44) | TACR1GPBAR1KCNH2 | |
| SCHEMBL5742325 | 0.77 | GABRP (0.54) | TACR1GPBAR1KCNH2KLRK1MICA | |
| SCHEMBL5742326 | 0.77 | GABRP (0.54) | TACR1GPBAR1KCNH2KLRK1MICA | |
| SCHEMBL6871097 | 0.77 | TACR1 (1.00) | TACR1GPBAR1 | |
| SCHEMBL5966324 | 0.76 | GPBAR1 (0.71) | TACR1GPBAR1 | |
| SCHEMBL7450697 | 0.75 | TACR1 (0.49) | TACR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1171419-B1 | BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR | HOFFMANN LA ROCHE (CH) | 2004-12-29 | — | — | EP | disclosed |
| US-6552088-B2 | 2'-methyl-biphenyl-2-carboxylic acid-(3,5-bis-trifluoromethyl-benzyl)-methyl-amide, for example; treating disease related to neurokinin 1 receptor | HOFFMANN-LA ROCHE INC. | 2003-04-22 | — | — | US | disclosed |
| US-20020040060-A1 | Biphenyl derivatives | BOS MICHAEL (CA) | 2002-04-04 | — | — | US | disclosed |
| EP-1171419-A1 | BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-16 | — | — | EP | disclosed |
| US-6291465-B1 | Biphenyl derivatives | HOFFMANN-LA ROCHE INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2000053572-A1 | BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040060-A1 | Biphenyl derivatives | NR1H4, NR1H2, NR1H3 | TACR1 16/4885GPBAR1 5/4885KCNH2 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.